459 related articles for article (PubMed ID: 34557143)
1. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
Front Neurol; 2021; 12():695696. PubMed ID: 34557143
[No Abstract] [Full Text] [Related]
2. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
5. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
6. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
8. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.
Tsiknia AA; Edland SD; Sundermann EE; Reas ET; Brewer JB; Galasko D; Banks SJ;
Mol Psychiatry; 2022 Oct; 27(10):4314-4322. PubMed ID: 35768637
[TBL] [Abstract][Full Text] [Related]
10. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
[TBL] [Abstract][Full Text] [Related]
11. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
12. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
13. Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline.
Lan G; Cai Y; Li A; Liu Z; Ma S; Guo T;
Ann Neurol; 2022 Dec; 92(6):1001-1015. PubMed ID: 36056679
[TBL] [Abstract][Full Text] [Related]
14. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
Huang Y; Li Y; Xie F; Guo Q
CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
[TBL] [Abstract][Full Text] [Related]
15. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Janelidze S; Mattsson N; Palmqvist S; Smith R; Beach TG; Serrano GE; Chai X; Proctor NK; Eichenlaub U; Zetterberg H; Blennow K; Reiman EM; Stomrud E; Dage JL; Hansson O
Nat Med; 2020 Mar; 26(3):379-386. PubMed ID: 32123385
[TBL] [Abstract][Full Text] [Related]
16. Association of plasma P-tau181 with memory decline in non-demented adults.
Therriault J; Benedet AL; Pascoal TA; Lussier FZ; Tissot C; Karikari TK; Ashton NJ; Chamoun M; Bezgin G; Mathotaarachchi S; Gauthier S; Saha-Chaudhuri P; Zetterberg H; Blennow K; Rosa-Neto P;
Brain Commun; 2021 Jul; 3(3):fcab136. PubMed ID: 34222875
[TBL] [Abstract][Full Text] [Related]
17. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
18. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.
Toledo JB; Xie SX; Trojanowski JQ; Shaw LM
Acta Neuropathol; 2013 Nov; 126(5):659-70. PubMed ID: 23812320
[TBL] [Abstract][Full Text] [Related]
20. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]